Legionnaire's Disease in Compromised Hosts.

Abstract

Legionnaire's disease (LD) is mainly reported in apparently immunocompetent patients. Among them, risk factors include chronic lung disease and smoking. However, LD is also well reported among immunocompromised patients, particularly those treated with anti-tumor necrosis factor alpha therapy, patients with hematological malignancy, and transplant patients. This article discusses the available data on immunity against Legionella spp, epidemiology, clinical presentation, diagnosis, and treatment of LD in immunocompromised patients.

• Authors: Fanny Lanternier, Florence Ader, Benoit Pilmis, Emilie Catherinot, Sophie Jarraud, Olivier Lortholary
• Journal: Infectious disease clinics of North America (Infect Dis Clin North Am) Vol. 31 Issue 1 Pg. 123-135 (03 2017) ISSN: 1557-9824 [Electronic] United States
• PMID: 28159172 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 Elsevier Inc. All rights reserved.

Chemical References

• Anti-Bacterial Agents

Topics

• Anti-Bacterial Agents (administration & dosage, therapeutic use)
• HIV Infections
• Humans
• Immunocompromised Host
• Legionnaires' Disease (complications, drug therapy, physiopathology)
• Neoplasms
• Transplant Recipients